Recent News

• 06.11.2025 - BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
• 06.10.2025 - BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
• 06.04.2025 - BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
• 05.13.2025 - BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights
• 05.01.2025 - BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles
• 04.29.2025 - BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025
• 03.11.2025 - BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Recent Filings

• 06.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.11.2025 - EX-99.1 EX-99.1
• 06.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.04.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.30.2025 - EFFECT Notice of Effectiveness
• 04.28.2025 - CORRESP Correspondence
• 04.25.2025 - UPLOAD SEC-generated letter